Search

Your search keyword '"Okumura, Shuichi"' showing total 26 results
Start Over Author "Okumura, Shuichi"
26 results on '"Okumura, Shuichi"'

2. Proceedings of the 71st General Meeting Sapporo, Japan, May 22–24, 1985

Author

Suyama, Masafumi, Ariyama, Jo, Higashi, Shunsaku, Mizumoto, Ryuji, Sato, Morio, Yamada, Ryusaku, Ohsaki, Yukio, Shimizu, Tatsuo, Takenaka, Kenji, Kanematsu, Takashi, Yumoto, Yasuhiro, Jinno, Kenji, Izawa, Kunihide, Tsuchiya, Ryoichi, Ohto, Masao, Sugiura, Nobuyuki, Kinoshita, Hiroaki, Sakai, Katsuji, Shingai, Yasushi, Kado, Yuji, Yamanaka, Naoki, Okamoto, Eizo, Toyosaka, Akihiko, Yabuki, Kohei, Abe, Kazuo, Ohshiba, Saburo, Hata, Yoshinobu, Nishi, Shinzo, Ishii, Nobuko, Nagataki, Shigenobu, Shimano, Takashi, Mori, Takesada, Ohkura, Hisanao, Hirohashi, Setsuo, Sawabu, Norio, Toya, Daishu, Sawabu, Norio, Toya, Daishu, Watanabe, Masahiko, Hirohashi, Setsuo, Okumura, Shuichi, Saitoh, Yoichi, Nakamura, Noriaki, Hirota, Masaki, Kanoh, Makoto, Kaneda, Haruo, Adachi, Kenji, Koyama, Shin, Hatakeyama, Katsuyoshi, Fukushima, Tsuneo, Tsuchiya, Shuji, Iwama, Takeo, Mishima, Yoshiro, Tsuburaya, T., Kushida, T., Uchino, J., Yamasaki, Susumu, Hasegawa, Hiroshi, Manabe, Tadao, Suzuki, Takashi, Yonemura, Yutaka, Sekoguchi, Tsutomu, Mizumoto, Ryuji, Ebata, Hidetaka, Hayashi, Hirokazu, Arakawa, Yasuyuki, Yasuda, Morihide, Inoue, Kazutomo, Hosotani, Ryo, Funakoshi, Akihiro, Nakano, Itsuro, Yamamura, T., Takahashi, T., Miyata, Masahiro, Nakao, Kazuyasu, Imamura, Mikio, Sato, Toshio, Kishimoto, Shinya, Kajiyama, Goro, Noda, Aiji, Hayakawa, Tetsuo, Nagata, Atsuo, Homma, Tatsuji, Miyake, Hirofumi, Harada, Hideo, Kimura, Toshinari, Sumi, Toshihiko, Miyasaka, Kyoko, Kitani, Kenichi, Yamauchi, H., Sato, T., Takahashi, Toshihisa, Wakabayashi, Toshishige, Konishi, Kohji, Izumi, Ryohei, Miyashita, Tadashi, Suzuki, Takashi, Tsunoda, Tsukasa, Tsuchiya, Ryoichi, Fujiwara, Akira, Okajima, Kunio, Tabuchi, Yoshiki, Saitoh, Yoichi, Takahashi, Hiroshi, Muramatsu, Yukio, Yamada, Tatsuya, Uehara, Koichiro, Mishima, Yoshio, Fukuda, Ichiro, Imaoka, Shingi, Hiramatsu, K., Ido, K., and Takahashi, Takashi

Published
1986
Full Text
View/download PDF

13. Experimental Studies on Fluosol Da Administration in Acute Pancreatitis

Author

Ohyanagi, Harumasa, Ohashi, Osamu, Nakayama, Shinichi, Yamamoto, Masahiro, Okumura, Shuichi, and Saitoh, Yoichi

Abstract

Therapeutic use of the perfluorochemical emulsion, Fluosol DA, in acute pancreatitis was experimentally discussed in view of maintaining the local blood flow and oxygen supply in the pancreas to avoid further aggravation of pancreatitis. Acute pancreatitis was induced by deoxycholate injection into the pancreatic duct in adult mongrel dogs. Fluosol DA or 6% hydroxyethylstarch (HES) solution as control was transfused at 20 ml/kg/hour for the first 3 hours.Fluosol DA and HES solution improved the depressed cardiac output and pancreatic blood flow to normal levels. Compared with HES solution, Fluosol DA administration revealed a prominent increase in oxygen tension in the pancreatic tissue, which had decreased severely from onset of pancreatitis. Fluosol DA administration brought about better preservation of pancreatic mitochondrial functions.Despite no significant differences in blood levels of other pancreatic enzymes between Fluosol DA and HES solution, the sharp decrease in plasma postheparin phospholipase A2 suggested the protection of involved systemic organs including pancreas.Thus, maintaining pancreatic blood flow and increasing the oxygen transport by Fluosol DA administration seemed to play a positive role in inhibiting the progress of pancreatitis, though improvement of survival rate in acute pancreatitis was incomplete by Fluosol DA administration alone.

Published
1988
Full Text
View/download PDF

16. A NEW TECHNIQUE OF PANCREATIC EXOCRINE DIVERSION TO THE ESOPHAGUS IN CANINE SEGMENTAL PANCREATIC AUTOTRANSPLANTATION

Author

KURODA, YOSHIKAZU, primary, ORITA, KOZO, additional, IWAGAKI, SOICHI, additional, NAKAYAMA, SHINICHI, additional, SUZUKI, YASUYUKI, additional, KAWAMURA, TAKASHI, additional, ONOYAMA, HIROHIKO, additional, ASHIDA, TAKUYA, additional, YAMAMOTO, KYOSUKE, additional, TANAKA, TATSUHIKO, additional, OKUMURA, SHUICHI, additional, and SAITOH, YOICHI, additional

Published
1987
Full Text
View/download PDF

19. STUDIES OF BENIGN BILIARY STRICTURE

Author

FUJII, Yasuhiro, primary, TANAKA, Tatsuhiko, additional, NAKAYAMA, Shinichi, additional, KO, Koichi, additional, UESAKA, Kunio, additional, ASHIDA, Takuya, additional, YAMAMOTO, Masahiro, additional, OKUMURA, Shuichi, additional, OHYANAGI, Harumasa, additional, and SAITOH, Yoichi, additional

Published
1987
Full Text
View/download PDF

23. Papillary hyperplasia of the pancreas

Author

Shimizu, Michio, primary, Itoh, Hiroshi, additional, Okumura, Shuichi, additional, Hashimoto, Kimio, additional, Hanioka, Keisuke, additional, Ohyanagi, Harumasa, additional, Yamamoto, Masahiro, additional, Kuroda, Yoshikazu, additional, Tanaka, Tatsuhiko, additional, and Saitoh, Yoichi, additional

Published
1989
Full Text
View/download PDF

24. [A case of TS-1 resistant recurrent gastric cancer with lung metastasis responding to TS-1 and irinotecan combination therapy].

Author

Kawamura S, Kataoka Y, Kimura H, Tei M, Hasegawa Y, Shimada E, and Okumura S

Subjects
Aged, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Combined Modality Therapy, Drug Administration Schedule, Drug Combinations, Humans, Irinotecan, Liver Neoplasms secondary, Liver Neoplasms surgery, Lung Neoplasms drug therapy, Male, Oxonic Acid administration & dosage, Pancreas surgery, Splenectomy, Stomach Neoplasms pathology, Stomach Neoplasms surgery, Tegafur administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Drug Resistance, Neoplasm, Gastrectomy, Lung Neoplasms secondary, Stomach Neoplasms drug therapy
Abstract

We report a case of TS-1-resistant recurrent gastric cancer with lung metastasis responding to TS-1 and irinotecan (CPT-11) combination therapy. A 72-year-old man underwent total gastrectomy with pancreaticosplenectomy for advanced gastric cancer on October 18, 2001, and partial hepatectomy for postoperative liver metastasis on August 22, 2002. In March 2004, a chest computed tomography scan revealed metastatic lesions in the bilateral lungs, and he received a single administration of TS-1, resulting in partial response. After 13 courses, this therapy was discontinued due to progressive disease. Then,TS-1 and CPT-11 combination therapy was chosen as the second-line chemotherapy. After 4 courses, a partial response was obtained in lung metastasis, and thereafter has been maintained. He has been treated on an outpatient basis because of no grade 3 or severer adverse reactions. TS-1 and CPT-11 combination therapy could be a promising regimen as the second-line chemotherapy for gastric cancer resistant to TS-1.

Published
2007

25. [A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy].

Author

Kawamura S, Yamagishi D, Tei M, Sumi Y, Shimada E, and Okumura S

Subjects
Anorexia chemically induced, Antineoplastic Combined Chemotherapy Protocols adverse effects, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Combined Modality Therapy, Drug Administration Schedule, Drug Combinations, Female, Humans, Irinotecan, Lymphatic Metastasis, Middle Aged, Nausea chemically induced, Neutropenia chemically induced, Oxonic Acid administration & dosage, Quality of Life, Stomach Neoplasms pathology, Stomach Neoplasms surgery, Survivors, Tegafur administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Gastrectomy, Lymph Nodes pathology, Stomach Neoplasms drug therapy
Abstract

We report a case of non-curatively resected gastric cancer successfully treated with TS-1 and irinotecan (CPT-11) combination therapy, resulting in long-term survival of 17 months. A 56-year-old woman underwent noncurative resection with total gastrectomy for advanced gastric cancer with severe lymph node metastasis on June 3, 2004. Postoperatively, She received TS-1 and CPT-11 combination therapy (TS-1 80 mg/m(2) day 1-21, CPT-11 80 mg/m(2) day 1, 15, every 5 weeks). However, due to grade 4 neutropenia, and grade 3 nausea and anorexia in the first course, both doses were reduced. Since then, no grade 3 or severer adverse reactions have been observed. After 5 courses, partial response to lymph node metastasis was obtained, and her quality of life was improved. Thus, TS-1 and CPT-11 combination therapy has been effective for 17 months, suggesting that it is promising for long-term administration and survival to continue it perseveringly.

Published
2006

26. [A case of non-curatively resected gastric cancer successfully treated over 3 years with biweekly paclitaxel therapy].

Author

Yamagishi D, Kawamura S, Tei M, Habara K, Sumi Y, Shimada E, and Okumura S

Subjects
Aged, Antineoplastic Agents, Phytogenic adverse effects, Drug Administration Schedule, Gastrectomy, Humans, Lymphatic Metastasis, Male, Neutropenia chemically induced, Paclitaxel adverse effects, Stomach Neoplasms pathology, Survivors, Antineoplastic Agents, Phytogenic administration & dosage, Lymph Nodes pathology, Paclitaxel administration & dosage, Stomach Neoplasms drug therapy
Abstract

We report a case of non-curatively resected gastric cancer successfully treated over 3 years with biweekly administration of paclitaxel. A 69-year-old man underwent non-curative resection with distal gastrectomy for advanced gastric cancer with remarkable lymph node metastasis on June 10, 2002. The metastatic lymph node (No. 8 a, 8 p and 12 a) linked up with the retroperitoneal node, making resection impossible. Postoperatively, he was initially treated with weekly administration of paclitaxel 100 mg/body (68 mg/m(2)) per week. However, due to grade 3 neutropenia in the first course, weekly administration was changed to biweekly administration with dose reduction to 60 mg/body (41 mg/m(2)), resulting in the continuation of paclitaxel therapy. Since then, no grade 3 or more severe adverse reactions have been observed. He has maintained NC for 3 years, and is still being treated on an outpatient basis at present. We believe that, in paclitaxel therapy for advanced gastric cancer, it is important for long-term survival to continue it perseveringly by dose reduction or change of schedule, when major adverse reactions are seen.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results